Maccura BiotechnologyLtd Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Wu Mingjian

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	9.2yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.5yrs

Jüngste Management Updates

Recent updates

Is Maccura BiotechnologyLtd (SZSE:300463) Using Too Much Debt?

Aug 01

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

May 28

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

May 01

Geschäftsführer

Wu Mingjian (47 yo)

9.2yrs

Amtszeit

CN¥1,280,000

Vergütung

Mr. Wu Mingjian serves as General Manager of Maccura Biotechnology Co. Ltd and serves as its Director since August 14, 2015. He served as Commercial Director and Finance Manager at Maccura Biotechnology Co...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Wu Mingjian	GM & Director	9.2yrs	CN¥1.28m	0.24% CN¥ 21.2m
Shan Yin	CFO & Director	1.9yrs	CN¥780.00k	0.043% CN¥ 3.8m
Shengguo Xu	Director of Marketing & Director	7.1yrs	CN¥1.20m	0.027% CN¥ 2.4m
Daiguo Fu	Independent Director	5.8yrs	CN¥100.00k	keine Daten
Hong Deng	Non-Employee Representative Supervisor	2.9yrs	keine Daten	0.036% CN¥ 3.2m
Deng Ming Wang	Director	14.8yrs	CN¥850.00k	7.5% CN¥ 664.3m
Lin Wang	Employee Representative Supervisor	14.8yrs	keine Daten	0.39% CN¥ 34.5m
Yong Tang	Chairman of the Board	14.8yrs	CN¥1.28m	11.22% CN¥ 993.0m
Yuan Zou	Chairman of Supervisor Board	7.9yrs	keine Daten	0.20% CN¥ 17.9m
Qi Lin Liu	Director	14.8yrs	CN¥730.00k	5.46% CN¥ 483.3m
Kaicheng Liang	Independent Director	2.8yrs	CN¥100.00k	keine Daten
Zhenzhong Liao	Independent Director	2.8yrs	CN¥100.00k	keine Daten

7.5yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 300463Die Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).

Maccura BiotechnologyLtd Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Maccura Biotechnology Co.Ltd, Annual General Meeting, Jun 03, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Maccura Biotechnology Co.Ltd to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 30%

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.095 in 2Q 2023)

Is Maccura BiotechnologyLtd (SZSE:300463) Using Too Much Debt?

Maccura Biotechnology Co.Ltd to Report First Half, 2024 Results on Aug 02, 2024

Maccura Biotechnology Co.Ltd Announces Final Profit Distribution Plan on A Shares for the Year 2023, Payable on July 3, 2024

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2023

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

Maccura Biotechnology Co.Ltd, Annual General Meeting, Jun 03, 2024

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

Maccura Biotechnology Co.Ltd Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.19 in 1Q 2023)

Maccura Biotechnology Co.Ltd to Report Q1, 2024 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment deteriorates as stock falls 19%

Maccura Biotechnology Co.Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd(SZSE:300463) dropped from Shenzhen Stock Exchange Component A Share Index

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.32 in 3Q 2022)

Consensus EPS estimates fall by 17%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.095 (vs CN¥0.33 in 2Q 2022)

Maccura Biotechnology Co.Ltd to Report First Half, 2023 Results on Jul 29, 2023

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2022

Price target decreased by 21% to CN¥20.86

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.34 in 1Q 2022)

Price target increased to CN¥26.33

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.48 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 2Q 2021)

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2021

Maccura Biotechnology Co.Ltd Approves Cash Dividend of for 202

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.48 (vs CN¥0.46 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.42 in 2Q 2020)

Maccura Biotechnology Co.Ltd Approves Final Dividend for the Year 2020

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.14 in 1Q 2020)

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 300 million worth of its shares.

New 90-day low: CN¥39.84

New 90-day low: CN¥41.24

New 90-day low: CN¥45.38

Price target raised to CN¥62.32

Third quarter earnings released

Maccura Biotechnology Co.Ltd announced that it expects to receive CNY 2.77 billion in funding

Maccura Biotechnology Co.Ltd to Report First Half, 2020 Results on Jul 31, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter